Hemodialysis and Peritoneal Dialysis Market: as CMS's newly finalized 2026 Medicare payment rate collides with B. Braun's move to vertically integrate its own dialysis concentrate supply, the industry's two largest cost levers, government reimbursement and raw material input costs, are both shifting in the same budget cycle, so dialysis provider margins over the next two years will depend as much on how effectively each operator manages these structural cost pressures as on patient volume growth, and manufacturers who can demonstrably lower a provider's per-treatment cost will hold real negotiating leverage regardless of clinical differentiation.

The global hemodialysis and peritoneal dialysis market size was USD 105.4 Billion in 2025 and is expected to register a revenue CAGR of 5.6% during the forecast period. Market revenue growth is driven by factors such as the sustained global scale of end-stage kidney disease requiring lifelong dialysis therapy, next-generation dialysis machine platforms improving treatment efficiency, and vertical integration among manufacturers securing input supply chains. The first driving factor is the sustained global scale of end-stage kidney disease, with USRDS data documenting more than 554,000 US patients receiving dialysis therapy and Fresenius Medical Care alone treating 299,352 patients across 3,675 clinics worldwide. In-centre hemodialysis services account for approximately 74% of total 2025 market revenue, reflecting the continued dominance of the traditional three-times-weekly in-centre treatment model globally. The second driving factor is next-generation dialysis machine platforms that improve treatment efficiency and clinical outcomes for both in-centre and home dialysis settings. The third driving factor is vertical integration among manufacturers securing their own input supply chains for dialysis concentrates and consumables. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a dialysis provider's per-treatment cost structure compounds across its entire patient population, which means even a modest improvement in machine efficiency or concentrate input cost translates into a substantial aggregate margin effect across a provider serving hundreds of thousands of patients receiving multiple treatments weekly. Because dialysis providers operate on government-set reimbursement rates that leave limited room to pass through rising input costs, a manufacturer that can demonstrably lower a provider's per-treatment machine, consumables, or concentrate cost captures real negotiating leverage precisely because that cost reduction directly protects the provider's margin under a reimbursement structure the provider cannot itself renegotiate. As a result, demand and revenue share are concentrating around manufacturers who can prove a genuine per-treatment cost advantage, and the forecast reflects this dynamic as a distinct driver of manufacturer competitive positioning independent of underlying patient volume growth. For instance, in 2025, B. Braun completed its acquisition of Intermedt, vertically integrating dialysis concentrate production and reducing operational overhead for clinics using its automated mixing systems, directly targeting the per-treatment cost structure that determines dialysis provider margin under fixed reimbursement rates. These are some of the key factors driving revenue growth of the market.

Because Medicare's End-Stage Renal Disease Prospective Payment System sets a fixed per-treatment base rate that covers the substantial majority of US dialysis patients, dialysis providers have limited ability to pass through rising input, labour, or facility costs to payers, which compresses margin even as underlying patient volume and treatment demand continue to grow.

Antitrust scrutiny of the market's concentrated provider structure is a second constraint, because the two largest US dialysis providers have historically controlled a substantial majority of the domestic market, and regulatory attention to this concentration, including federal antitrust investigation activity, introduces genuine uncertainty about future consolidation and competitive dynamics in the sector.

Home dialysis adoption barriers are a third constraint, since despite documented clinical and cost advantages, home hemodialysis and home peritoneal dialysis adoption continues to lag in-centre treatment in most markets due to patient training requirements, caregiver support needs, and clinical comfort with the home modality among both patients and referring physicians.

These factors substantially limit hemodialysis and peritoneal dialysis market growth over the forecast period.

The clearest driver of demand is the sustained global scale of end-stage kidney disease, which requires lifelong dialysis therapy for patients without access to kidney transplantation. Dialysis is a life-sustaining therapy with no substitute short of transplantation, so the patient population requiring treatment grows in direct proportion to end-stage kidney disease incidence and prevalence, independent of any single provider or manufacturer's competitive strategy. In-centre hemodialysis services account for approximately 74% of total 2025 market revenue, and USRDS 2024 data documents more than 554,000 US patients receiving dialysis therapy, with Fresenius Medical Care alone treating 299,352 patients across 3,675 clinics worldwide and DaVita serving 237,000 US patients across approximately 3,000 centres. The effect on the market is that baseline dialysis demand remains structurally resilient and predictable, providing a stable revenue floor beneath the market's competitive and cost-structure dynamics. These are some of the key factors driving revenue growth of the market.

The second driver is the continued introduction of next-generation dialysis machine platforms that improve treatment efficiency and clinical outcomes for both in-centre and home dialysis settings. Hemodiafiltration-capable machines can achieve superior clearance of larger uremic toxin molecules compared to conventional hemodialysis, so a machine platform that adds this capability directly expands the clinical value a provider can offer without requiring a new treatment modality altogether. In June 2025, Fresenius Medical Care received FDA 510(k) clearance for its hemodiafiltration-capable 5008X CAREsystem, with the company planning full US commercialisation in 2026. The effect on the market is that established dialysis machine manufacturers are extending their installed base's clinical capability through software and hardware upgrades rather than requiring providers to adopt an entirely new platform. These are some of the key factors driving revenue growth of the market.

Fresenius Medical Care alone treats 299,352 patients across 3,675 clinics worldwide. The scale of the world's largest dialysis operators means even incremental per-treatment cost or efficiency improvements compound into substantial aggregate financial effects.

The third driver is vertical integration among manufacturers securing their own input supply chains for dialysis concentrates and consumables, a strategy that directly targets the per-treatment cost structure determining provider margin under fixed reimbursement. Because dialysis providers operate under government-set reimbursement rates with limited ability to pass through rising input costs, a manufacturer that can demonstrably lower concentrate or consumable costs through vertical integration and automated production offers providers a genuine margin-protection benefit that is otherwise unavailable to them. In 2025, B. Braun completed its acquisition of Intermedt, vertically integrating dialysis concentrate production, with reported data indicating a meaningful reduction in operational overhead for clinics using the company's automated mixing systems. The effect on the market is that manufacturer competitive positioning increasingly depends on demonstrable per-treatment cost advantage, not only on clinical differentiation, given the reimbursement structure constraining provider pricing flexibility. These are some of the key factors driving revenue growth of the market.

However, the hemodialysis and peritoneal dialysis market faces severe adoption constraints from fixed government reimbursement rates that limit provider pricing flexibility and antitrust scrutiny of the market's concentrated provider structure.

Because Medicare's End-Stage Renal Disease Prospective Payment System sets a fixed per-treatment base rate, established at USD 281.71 per treatment under the CY2026 ESRD PPS Final Rule issued by CMS in November 2025, dialysis providers have limited ability to pass through rising input, labour, or facility costs to payers, which compresses margin even as underlying patient volume and treatment demand continue to grow.

Antitrust scrutiny of the market's concentrated provider structure compounds this, because the two largest US dialysis providers have historically controlled a substantial majority of the domestic market, and regulatory attention to this concentration, including federal antitrust investigation activity, introduces genuine uncertainty about future consolidation and competitive dynamics in the sector.

Home dialysis adoption barriers are the third constraint, since despite documented clinical and cost advantages, home hemodialysis and home peritoneal dialysis adoption continues to lag in-centre treatment in most markets due to patient training requirements, caregiver support needs, and clinical comfort with the home modality among both patients and referring physicians.

These factors substantially limit hemodialysis and peritoneal dialysis market growth over the forecast period.

Based on product, the global hemodialysis and peritoneal dialysis market is segmented into dialysis services, dialysis machines and cyclers, dialyzers and membranes, PD solutions and concentrates, and vascular access devices. In-centre hemodialysis services hold the largest revenue share, accounting for approximately 74% of total market revenue, because the traditional three-times-weekly in-centre treatment model remains the dominant care pathway globally, which suits a market where established, provider-delivered care still commands the overwhelming majority of total spend. Home dialysis services, spanning both home hemodialysis and home peritoneal dialysis, remain a smaller but growing category given the clinical and lifestyle advantages some patients and providers increasingly prioritise. Home dialysis services are expected to register the fastest revenue growth rate in the global hemodialysis and peritoneal dialysis market over the forecast period, driven by Fresenius Medical Care's NxStage System One home hemodialysis platform and comparable home-focused technologies, which is why the largest providers continue to invest in expanding home modality capacity.

Hemodialysis modality is expected to account for the largest revenue share in the global hemodialysis and peritoneal dialysis market during the forecast period

Based on modality, the global hemodialysis and peritoneal dialysis market is segmented into hemodialysis and peritoneal dialysis. Hemodialysis holds the largest revenue share, because it remains the most common dialysis modality globally, both in-centre and at home, which ties directly back to the scale of established in-centre treatment infrastructure described in the market's primary demand driver. Peritoneal dialysis is expected to register the fastest revenue growth rate in the global hemodialysis and peritoneal dialysis market over the forecast period, driven by its suitability for home-based treatment and growing clinical and policy emphasis on home dialysis modalities, which is why Baxter's Vantive renal care business and comparable PD-focused manufacturers continue to prioritise PD solution and cycler innovation.

In-centre hemodialysis patient setting is expected to account for the largest revenue share in the global hemodialysis and peritoneal dialysis market during the forecast period

Based on patient setting, the global hemodialysis and peritoneal dialysis market is segmented into in-centre hemodialysis, home hemodialysis, and home peritoneal dialysis. In-centre hemodialysis holds the largest revenue share, reflecting the scale of established clinic infrastructure operated by Fresenius Medical Care, DaVita, and comparable providers globally. Home hemodialysis is expected to register the fastest revenue growth rate in the global hemodialysis and peritoneal dialysis market over the forecast period, driven by patient preference for treatment flexibility and documented clinical outcome advantages associated with more frequent home-based treatment schedules.

Based on regional analysis, the hemodialysis and peritoneal dialysis market in North America accounted for largest revenue share in 2025. The United States leads because Medicare's universal ESRD coverage entitlement creates a uniquely large and stable reimbursement-backed patient population, and because Fresenius Medical Care, DaVita, and Baxter's Vantive business all maintain substantial US commercial and clinical operations. The CMS CY2026 ESRD Prospective Payment System Final Rule, issued in November 2025, directly shapes provider economics across the entire US dialysis industry. The scale of the US Medicare-covered dialysis population anchors a domestic market large enough to sustain the industry's most capital-intensive equipment and services investment.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent the two largest national markets within the region, with Nipro and Nikkiso both maintaining substantial regional manufacturing and clinical presence. China's rapidly expanding dialysis infrastructure investment and rising chronic kidney disease prevalence leave considerably more room for growth than in the already established North American market.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. Fresenius Medical Care and B. Braun, both headquartered in Germany, maintain their primary global manufacturing and commercial base in Europe. The result is steady rather than rapid growth, shaped more by national health system reimbursement structures than by underlying patient demand.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding dialysis centre infrastructure driving demand growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised dialyzer membrane and machine components that Latin American providers depend on, an effect expected to run through 2026 and slow hemodialysis and peritoneal dialysis equipment adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding dialysis centre network and the UAE's regional distribution hubs represent the primary investment centres for hemodialysis and peritoneal dialysis adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the dialysis infrastructure needed to support advanced treatment modalities at scale.